NASDAQ:SEEL Seelos Therapeutics (SEEL) Stock Forecast, Price & News $0.18 +0.01 (+5.75%) (As of 09/29/2023 ET) Add Compare Share Share Today's Range$0.17▼$0.2050-Day Range$0.16▼$1.5852-Week Range$0.15▼$1.66Volume5.46 million shsAverage Volume9.62 million shsMarket Capitalization$23.53 millionP/E RatioN/ADividend YieldN/APrice Target$2.33 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Seelos Therapeutics MarketRank™ ForecastAnalyst RatingHold2.33 Rating ScoreUpside/Downside1,168.1% Upside$2.33 Price TargetShort InterestHealthy4.81% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.77Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.43) to ($0.25) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.88 out of 5 starsMedical Sector766th out of 970 stocksPharmaceutical Preparations Industry364th out of 450 stocks 3.2 Analyst's Opinion Consensus RatingSeelos Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $2.33, Seelos Therapeutics has a forecasted upside of 1,168.1% from its current price of $0.18.Amount of Analyst CoverageSeelos Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.81% of the outstanding shares of Seelos Therapeutics have been sold short.Short Interest Ratio / Days to CoverSeelos Therapeutics has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Seelos Therapeutics has recently increased by 1.99%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldSeelos Therapeutics does not currently pay a dividend.Dividend GrowthSeelos Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SEEL. Previous Next 3.2 News and Social Media Coverage News SentimentSeelos Therapeutics has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Seelos Therapeutics this week, compared to 1 article on an average week.Search Interest8 people have searched for SEEL on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows6 people have added Seelos Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 20% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Seelos Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.40% of the stock of Seelos Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 17.97% of the stock of Seelos Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Seelos Therapeutics are expected to grow in the coming year, from ($0.43) to ($0.25) per share. Previous Next See Top Rated MarketRank™ Stocks Here About Seelos Therapeutics (NASDAQ:SEEL) StockSeelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, a peptidic inhibitor to treat patients with PD; SLS-008 for the treatment of pediatric indications; SLS-004 for the treatment of PD; SLS-010, an H3 receptor antagonist; and SLS-012. The company was founded in 2016 and is headquartered in New York, New York.Read More SEEL Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SEEL Stock News HeadlinesSeptember 27, 2023 | msn.comSeelos Therapeutics' Aggressive Alzheimer's Hopeful Candidate Shows Encouraging Preclinical ActivitySeptember 27, 2023 | markets.businessinsider.comSeelos Announces Encouraging Data From Study Of SLS-005 In Preclinical Model Of Alzheimer's DiseaseSeptember 30, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.September 27, 2023 | finance.yahoo.comSeelos Therapeutics Announces Encouraging Data from an In Vivo Study of SLS-005 in an Aggressive Preclinical Model of Alzheimer's DiseaseSeptember 23, 2023 | msn.comGuggenheim Downgrades Seelos Therapeutics (SEEL)September 23, 2023 | americanbankingnews.comSeelos Therapeutics (NASDAQ:SEEL) Price Target Cut to $1.00 by Analysts at BenchmarkSeptember 23, 2023 | americanbankingnews.comSeelos Therapeutics (NASDAQ:SEEL) Downgraded to "Neutral" at GuggenheimSeptember 22, 2023 | marketwatch.comSeelos Therapeutics Hits Another New Low After Stock Sale >SEELSeptember 30, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.September 22, 2023 | nasdaq.comBenchmark Maintains Seelos Therapeutics (SEEL) Speculative Buy RecommendationSeptember 22, 2023 | markets.businessinsider.comWhere Seelos Therapeutics Stands With AnalystsSeptember 22, 2023 | americanbankingnews.comSeelos Therapeutics (NASDAQ:SEEL) Rating Lowered to Neutral at Cantor FitzgeraldSeptember 21, 2023 | investorplace.comWhy Is Seelos Therapeutics (SEEL) Stock Down 25% Today?September 20, 2023 | marketwatch.comSeelos Therapeutics Shares Slide Premarket on SLS-002 Study Shortfall >SEELSeptember 20, 2023 | msn.comWhy Is Depression Focused Seelos Therapeutics Stock Plunging Today?September 20, 2023 | marketwatch.comSeelos Therapeutics Shares Plumb New Depths on Study Shortfall >SEELSeptember 20, 2023 | msn.comUS Futures Rise Modestly Pre-Bell as Investors Await Fed Rate DecisionSeptember 20, 2023 | msn.comSeelos Therapeutics’ stock slides 36% after trial of treatment for suicidal ideation has too few patients to meet endpointSeptember 20, 2023 | markets.businessinsider.comSeelos Therapeutics: SLS-002 Phase II Study Fails To Meet Primary Endpoint On Limited Sample SizeSeptember 20, 2023 | proactiveinvestors.comSeelos tumbles 66% as depression drug fails after it recruits too few patientsSeptember 20, 2023 | finance.yahoo.comSeelos Therapeutics Announces Top Line Results from SLS-002 Phase II Study in Adults with Major Depressive Disorder at Imminent Risk of SuicideSeptember 14, 2023 | finance.yahoo.com7 Biotech Stocks to Sell in September Before They Crash & BurnAugust 22, 2023 | markets.businessinsider.com4 Analysts Have This to Say About Seelos TherapeuticsAugust 16, 2023 | msn.comCantor Fitzgerald Reiterates Seelos Therapeutics (SEEL) Overweight RecommendationAugust 14, 2023 | finance.yahoo.comSeelos Therapeutics Provides Second Quarter 2023 Clinical UpdateAugust 13, 2023 | finance.yahoo.comSeelos Therapeutics' (NASDAQ:SEEL) investors will be pleased with their decent 52% return over the last yearAugust 3, 2023 | markets.businessinsider.comPsyched: Portugal Decriminalizes Synthetic Drugs, Anorexia And Psilocybin, LSD Microdosing, California & MoreSee More Headlines Receive SEEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Seelos Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address SEEL Company Calendar Today9/30/2023Next Earnings (Estimated)10/06/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SEEL CUSIPN/A CIK1017491 Webwww.seelostherapeutics.com Phone(646) 293-2100Fax858-436-8155Employees16Year Founded2016Price Target and Rating Average Stock Price Forecast$2.33 High Stock Price Forecast$4.00 Low Stock Price Forecast$1.00 Forecasted Upside/Downside+1,168.1%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-73,530,000.00 Net MarginsN/A Pretax Margin-7,096.85% Return on Equity-10,287.49% Return on Assets-328.75% Debt Debt-to-Equity RatioN/A Current Ratio0.21 Quick Ratio0.21 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.10) per share Price / Book-1.84Miscellaneous Outstanding Shares127,890,000Free Float119,706,000Market Cap$23.53 million OptionableNot Optionable Beta1.90 Social Links Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Raj Mehra J.D. (Age 63)Ph.D., Founder, Chairman, CEO & Pres Comp: $854.73kMr. Michael J. Golembiewski (Age 51)Chief Financial Officer Comp: $454.83kMs. Kimberly FarrandSr. Director of Clinical Devel. & OperationsMr. Anthony MarcianoChief Communications OfficerGopal Krishna Ph.D.Head of Manufacturing & Technical OperationsTim Whitaker M.D.Chief Medical OfficerMs. Karen FusaroSr. VP & Head of Clinical OperationsMore ExecutivesKey CompetitorsSynlogicNASDAQ:SYBXVallon PharmaceuticalsNASDAQ:VLONIndaptus TherapeuticsNASDAQ:INDPSensei BiotherapeuticsNASDAQ:SNSELumos PharmaNASDAQ:LUMOView All CompetitorsInstitutional OwnershipWolverine Trading LLCSold 13,100 shares on 8/23/2023Ownership: 0.000%Woodline Partners LPBought 573,986 shares on 8/15/2023Ownership: 0.471%Citadel Advisors LLCBought 10,200 shares on 8/15/2023Ownership: 0.000%State of WyomingBought 33,417 shares on 8/14/2023Ownership: 0.027%Two Sigma Securities LLCBought 31,321 shares on 8/14/2023Ownership: 0.026%View All Institutional Transactions SEEL Stock - Frequently Asked Questions Should I buy or sell Seelos Therapeutics stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Seelos Therapeutics in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" SEEL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SEEL, but not buy additional shares or sell existing shares. View SEEL analyst ratings or view top-rated stocks. What is Seelos Therapeutics' stock price forecast for 2023? 3 brokers have issued twelve-month price objectives for Seelos Therapeutics' stock. Their SEEL share price forecasts range from $1.00 to $4.00. On average, they expect the company's stock price to reach $2.33 in the next twelve months. This suggests a possible upside of 1,168.1% from the stock's current price. View analysts price targets for SEEL or view top-rated stocks among Wall Street analysts. How have SEEL shares performed in 2023? Seelos Therapeutics' stock was trading at $0.6790 at the beginning of 2023. Since then, SEEL stock has decreased by 72.9% and is now trading at $0.1840. View the best growth stocks for 2023 here. When is Seelos Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, October 6th 2023. View our SEEL earnings forecast. What ETF holds Seelos Therapeutics' stock ? AdvisorShares Psychedelics ETF holds 312,582 shares of SEEL stock, representing 5.70% of its portfolio. What other stocks do shareholders of Seelos Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Seelos Therapeutics investors own include VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Tonix Pharmaceuticals (TNXP), Vaxart (VXRT), Biocept (BIOC), Onconova Therapeutics (ONTX), Co-Diagnostics (CODX), Heat Biologics (HTBX), iBio (IBIO) and OPKO Health (OPK). What is Seelos Therapeutics' stock symbol? Seelos Therapeutics trades on the NASDAQ under the ticker symbol "SEEL." How do I buy shares of Seelos Therapeutics? Shares of SEEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Seelos Therapeutics' stock price today? One share of SEEL stock can currently be purchased for approximately $0.18. How much money does Seelos Therapeutics make? Seelos Therapeutics (NASDAQ:SEEL) has a market capitalization of $23.53 million. How can I contact Seelos Therapeutics? Seelos Therapeutics' mailing address is 300 PARK AVENUE 12TH FLOOR, NEW YORK NY, 10022. The official website for the company is www.seelostherapeutics.com. The company can be reached via phone at (646) 293-2100, via email at anthony.marciano@seelostx.com, or via fax at 858-436-8155. This page (NASDAQ:SEEL) was last updated on 9/30/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Seelos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.